Cargando…
Efficacy and safety of fondaparinux versus enoxaparin in patients undergoing percutaneous coronary intervention treated with the glycoprotein IIb/IIIa inhibitor tirofiban
BACKGROUND: In worldwide, the mortality rate of acute myocardial infarction (AMI) raises year by year. Although the applications of percutaneous coronary intervention (PCI) and anticoagulants effectively reduce the mortality of patients with acute coronary syndrome (ACS), but also increase the incid...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4847352/ https://www.ncbi.nlm.nih.gov/pubmed/27123313 http://dx.doi.org/10.1186/s40779-016-0081-6 |
_version_ | 1782429199736242176 |
---|---|
author | Zhao, Xin Yang, Xiao-Xu Ji, Su-Zhen Wang, Xiao-Zeng Wang, Li Gu, Chong-Huai Ren, Li-Li Han, Ya-Ling |
author_facet | Zhao, Xin Yang, Xiao-Xu Ji, Su-Zhen Wang, Xiao-Zeng Wang, Li Gu, Chong-Huai Ren, Li-Li Han, Ya-Ling |
author_sort | Zhao, Xin |
collection | PubMed |
description | BACKGROUND: In worldwide, the mortality rate of acute myocardial infarction (AMI) raises year by year. Although the applications of percutaneous coronary intervention (PCI) and anticoagulants effectively reduce the mortality of patients with acute coronary syndrome (ACS), but also increase the incidence of bleeding. Therefore, drugs with stable anticoagulant effects are urgently required. METHODS: We enrolled 894 patients with acute coronary syndrome who underwent percutaneous coronary intervention in Shenyang Northern Hospital from February 2010 to May 2012; 430 patients were included in the fondaparinux group (2.5 mg/d), and 464 were included in the enoxaparin group (1 mg/kg twice daily). Fondaparinux and enoxaparin were applied for 3–7 days. All patients were treated with tirofiban (10 μg/kg for 3 min initially and 0.15 μg/(kg · min) for 1 to 3 days thereafter). The primary efficacy endpoint was the incidence of a major adverse cerebrovascular or cardiovascular event. The primary safety endpoint was bleeding within 30 days and 1 year after percutaneous coronary intervention. RESULTS: One-year data were available for 422 patients in the fondaparinux group and for 453 in the enoxaparin group. The incidence of a major adverse cerebrovascular or cardiovascular event (10.9 % vs 12.6 %, P = 0.433) and cardiac mortality (0.5 % vs 1.5 %, P = 0.116) were generally lower in the fondaparinux group than in the enoxaparin group, although the differences were not significant. Compared with the enoxaparin group, the fondaparinux group had a significantly decreased rate of bleeding at 30 days (0.9 % vs 2.8 %) and 1 year (2.4 % vs 5.4 %). In addition, the rate of major bleeding events was lower in the fondaparinux group, but this difference was not significant (0.2 % vs 0.9 %, 0.2 % vs 1.1 %). CONCLUSIONS: In tirofiban-treated patients with acute coronary syndrome undergoing percutaneous coronary intervention, fondaparinux presented similar efficacy for ischemia events as enoxaparin. However, fondaparinux significantly decreased the incidence of bleeding, thus providing safer anticoagulation therapy. |
format | Online Article Text |
id | pubmed-4847352 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-48473522016-04-28 Efficacy and safety of fondaparinux versus enoxaparin in patients undergoing percutaneous coronary intervention treated with the glycoprotein IIb/IIIa inhibitor tirofiban Zhao, Xin Yang, Xiao-Xu Ji, Su-Zhen Wang, Xiao-Zeng Wang, Li Gu, Chong-Huai Ren, Li-Li Han, Ya-Ling Mil Med Res Research BACKGROUND: In worldwide, the mortality rate of acute myocardial infarction (AMI) raises year by year. Although the applications of percutaneous coronary intervention (PCI) and anticoagulants effectively reduce the mortality of patients with acute coronary syndrome (ACS), but also increase the incidence of bleeding. Therefore, drugs with stable anticoagulant effects are urgently required. METHODS: We enrolled 894 patients with acute coronary syndrome who underwent percutaneous coronary intervention in Shenyang Northern Hospital from February 2010 to May 2012; 430 patients were included in the fondaparinux group (2.5 mg/d), and 464 were included in the enoxaparin group (1 mg/kg twice daily). Fondaparinux and enoxaparin were applied for 3–7 days. All patients were treated with tirofiban (10 μg/kg for 3 min initially and 0.15 μg/(kg · min) for 1 to 3 days thereafter). The primary efficacy endpoint was the incidence of a major adverse cerebrovascular or cardiovascular event. The primary safety endpoint was bleeding within 30 days and 1 year after percutaneous coronary intervention. RESULTS: One-year data were available for 422 patients in the fondaparinux group and for 453 in the enoxaparin group. The incidence of a major adverse cerebrovascular or cardiovascular event (10.9 % vs 12.6 %, P = 0.433) and cardiac mortality (0.5 % vs 1.5 %, P = 0.116) were generally lower in the fondaparinux group than in the enoxaparin group, although the differences were not significant. Compared with the enoxaparin group, the fondaparinux group had a significantly decreased rate of bleeding at 30 days (0.9 % vs 2.8 %) and 1 year (2.4 % vs 5.4 %). In addition, the rate of major bleeding events was lower in the fondaparinux group, but this difference was not significant (0.2 % vs 0.9 %, 0.2 % vs 1.1 %). CONCLUSIONS: In tirofiban-treated patients with acute coronary syndrome undergoing percutaneous coronary intervention, fondaparinux presented similar efficacy for ischemia events as enoxaparin. However, fondaparinux significantly decreased the incidence of bleeding, thus providing safer anticoagulation therapy. BioMed Central 2016-04-27 /pmc/articles/PMC4847352/ /pubmed/27123313 http://dx.doi.org/10.1186/s40779-016-0081-6 Text en © Zhao et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Zhao, Xin Yang, Xiao-Xu Ji, Su-Zhen Wang, Xiao-Zeng Wang, Li Gu, Chong-Huai Ren, Li-Li Han, Ya-Ling Efficacy and safety of fondaparinux versus enoxaparin in patients undergoing percutaneous coronary intervention treated with the glycoprotein IIb/IIIa inhibitor tirofiban |
title | Efficacy and safety of fondaparinux versus enoxaparin in patients undergoing percutaneous coronary intervention treated with the glycoprotein IIb/IIIa inhibitor tirofiban |
title_full | Efficacy and safety of fondaparinux versus enoxaparin in patients undergoing percutaneous coronary intervention treated with the glycoprotein IIb/IIIa inhibitor tirofiban |
title_fullStr | Efficacy and safety of fondaparinux versus enoxaparin in patients undergoing percutaneous coronary intervention treated with the glycoprotein IIb/IIIa inhibitor tirofiban |
title_full_unstemmed | Efficacy and safety of fondaparinux versus enoxaparin in patients undergoing percutaneous coronary intervention treated with the glycoprotein IIb/IIIa inhibitor tirofiban |
title_short | Efficacy and safety of fondaparinux versus enoxaparin in patients undergoing percutaneous coronary intervention treated with the glycoprotein IIb/IIIa inhibitor tirofiban |
title_sort | efficacy and safety of fondaparinux versus enoxaparin in patients undergoing percutaneous coronary intervention treated with the glycoprotein iib/iiia inhibitor tirofiban |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4847352/ https://www.ncbi.nlm.nih.gov/pubmed/27123313 http://dx.doi.org/10.1186/s40779-016-0081-6 |
work_keys_str_mv | AT zhaoxin efficacyandsafetyoffondaparinuxversusenoxaparininpatientsundergoingpercutaneouscoronaryinterventiontreatedwiththeglycoproteiniibiiiainhibitortirofiban AT yangxiaoxu efficacyandsafetyoffondaparinuxversusenoxaparininpatientsundergoingpercutaneouscoronaryinterventiontreatedwiththeglycoproteiniibiiiainhibitortirofiban AT jisuzhen efficacyandsafetyoffondaparinuxversusenoxaparininpatientsundergoingpercutaneouscoronaryinterventiontreatedwiththeglycoproteiniibiiiainhibitortirofiban AT wangxiaozeng efficacyandsafetyoffondaparinuxversusenoxaparininpatientsundergoingpercutaneouscoronaryinterventiontreatedwiththeglycoproteiniibiiiainhibitortirofiban AT wangli efficacyandsafetyoffondaparinuxversusenoxaparininpatientsundergoingpercutaneouscoronaryinterventiontreatedwiththeglycoproteiniibiiiainhibitortirofiban AT guchonghuai efficacyandsafetyoffondaparinuxversusenoxaparininpatientsundergoingpercutaneouscoronaryinterventiontreatedwiththeglycoproteiniibiiiainhibitortirofiban AT renlili efficacyandsafetyoffondaparinuxversusenoxaparininpatientsundergoingpercutaneouscoronaryinterventiontreatedwiththeglycoproteiniibiiiainhibitortirofiban AT hanyaling efficacyandsafetyoffondaparinuxversusenoxaparininpatientsundergoingpercutaneouscoronaryinterventiontreatedwiththeglycoproteiniibiiiainhibitortirofiban |